Laxmi Dental Ltd Q2 FY27 Results

INR79.5 Cr is highest but YoY 10% below FY27 guidance of 15–20%

Domestic lab +22.7%, aligner +23.5%, pediatric +16.7%, but scanner -60% YoY

EBITDA 19.2% vs 15.3% prior, PAT margin 12.3% matches; gross margin 76.9% vs 68.5% prior year

EBITDA +38.5% YoY, PAT +17.6% YoY, gross margin +840 bps; sequential PAT -2.7%, scanner sales collapsed

Launched 'Pink Revolution' subscription model (₹50k deposit + ₹3k monthly), 25k monthly business commitment. Q2 sales ₹3.5 Cr (vs ₹8.9 Cr FY26) signal model transition, not demand collapse.

Announced hub-and-spoke model with target 78% digital today, aiming 90%+ digitization. Digital adoption drives recurring revenue and operational efficiency.

IPO proceeds (₹848.1 Cr unutilized) allocated: ₹27+ Cr land/building, ₹21+ Cr machinery, for Palghar facility. Transition by end FY28. Prior call had vague 'capex planned' language.

Appointed US CEO, opening US lab. Now present in 90–100 countries (vs prior undefined international footprint). Hybrid lab model for international (digital in India, local presence as needed).

H1 FY27 revenue +33% but profit share -35% due to startup tax benefit expiry (3-year window ended). Expected to normalize in FY28 as benefit was always temporary.

Majority is clinics, not hospitals. Present in 300+ cities across India, not concentrated in Top 10. Tier 1, 2, 3 cities all growing, with East emerging as new frontier alongside established South/West/North.

Tier 1 has scanners for digitization; Tier 2/3 less access. We deliver aligner in phases, leveraging software capability and 4-by-4 logistics model to offer affordability. Education-driven approach through key opinion leaders in Tier 2/3.

Hybrid model: finished products (aligners, zirconia crowns) made in India or standardized output from US. India handles digital design, custom sheets. Only labor-intensive tasks and AI automation in respective country. Not 100% replica of Mumbai setup.

Focused on digitalizing existing network (78% today, target 90%+) rather than adding clinics immediately. Hub-and-spoke model increases wallet share per dentist. In-store growth visible across spokes; expanded footprint planned once digitization reaches 90%+.

Startup tax benefit expired after 3 years; now regular tax applies. No margin contraction. This is a one-time impact; profitability will normalize in FY28 as the base adjusts.

₹50k deposit, ₹3k monthly subscription, ₹25k monthly business commitment. Flexible: can be deposit-rent-subscription or outright buy. Launched 2.5 weeks ago; few thousand leads received. Deployment speed is quick, so ROI improves with volume.

Mix of both. Scanner decline (lower margin) offset by better product mix and digitization. Gross margin stable at 77%, historically 75–77% range. Upside from people and process efficiency, AI automation; downside from higher marketing/freight, scanner business. Long-term formula: sales-driven growth + people cost control + process efficiency.

Direct (13.2 Cr) and B2B raw material (11.5 Cr); profitability is good on both. B2C delivers aligner to clinic; B2B supplies raw material to India and international labs. Good realization on both; B2C branded (Illusion, Kareena), B2B supply.

Credit terms 30–60 days, similar to India. FX impact ~8–10% YoY constant currency growth, depends on month and realization timing. Not constant.

Top 2–3 global players exist; we aim to be among them. Trust and scale matter. Competitive pressure in 1–2 quarters possible, but experience and established relationships (36 years) are defensible. International expansion same strategy: trust, quality, local presence.

Subscription launched ~2.5 weeks ago. Few thousand leads received. Deployment pace very quick if engaged. Q2 limited as subscription campaign just live. Next quarter should show meaningful numbers if adoption materializes post-Diwali.

New facility 1.25–1.5 lakh sq ft, 3–3.5x current. Will be hybrid: digital (India), finished products made locally in target country. Scalable without 100% replica. Capacity for volume growth + automation.

2 models: Model 1 (deposit-subscription with commitment); Model 2 (outright buy). Still accepting outright sales. Lock scanners not a risk; flexibility exists. Seeing sales funnel growth for both scenarios.

No decline; 76.9% is an increase from 68.5% prior year. Quarter-on-quarter variations depend on product mix and scanner contribution. Excluding scanner, 77–78%. Scanner at 19% margins. Range is 75–77% historically.

Hub-and-spoke consolidates billing for multi-clinic dentists. Single account manager reduces friction, increases wallet share. Visible in-store growth trends; next phase is footprint expansion once 90%+ digitization achieved.

Q2 at 10% YoY, H1 at 12.7% YoY. Company not on pace; management did not reaffirm or adjust on this call.

Q2 at 19.2% and H1 at 19.2%; well within range. Gross margin stable 75–77% historically, currently 76.9%.

IPO proceeds allocated. Construction timeline expected by end FY28. No update on spend pace or delays on call.

Scanner sales fell 60% YoY (₹8.9 Cr to ₹3.5 Cr). Subscription model launched 2.5 weeks ago with few thousand leads. Dentist adoption and ₹25k/month commitment success are unproven.

H1 FY27 Kids-e-Dental revenue +33% YoY but profit share fell 35%, driven by startup tax benefit expiry after 3 years. Underlying margin improvement unclear.

Q2 revenue growth 10% YoY vs FY27 guidance of 15–20%. H1 at 12.7%. Domestic lab growth 22.7% YoY is solid, but scanner collapse and overall slowdown signal execution shortfall.

New facility 1.25–1.5 lakh sq ft, planned transition by end FY28. Capex ₹27+ Cr (land/building) + ₹21+ Cr (machinery) from IPO proceeds. Transition complexity and margin impact during migration unquantified.

US lab opening with appointed CEO, international presence in 90–100 countries. Hybrid lab model (digital in India, local for custom/labor) requires multi-country coordination and local expertise.

Aligner landscape has top 2–3 global players, local Indian brands, and new entrants. Pricing power and market share face pressure in 3–5 years as market rationalizes.